ClinicalTrials.Veeva

Menu
O

Optimed Research, LTD | Optimed Research, LTD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Risankizumab
ABT-494
Lanadelumab
Ecallantide
Tanezumab
Dupilumab
Bococizumab
STAR-0215
DX-88

Parent organization

This site is a part of Optimed Research, LTD

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 78 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: Placebo
Drug: BLU-5937

This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due...

Active, not recruiting
HAE
Hereditary Angioedema
Genetic: Dose 7 of BMN 331
Genetic: Dose 4 of BMN 331

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with here...

Enrolling
Hereditary Angioedema
Drug: STAR-0215

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and...

Enrolling
Primary Immunodeficiency Diseases (PID)
Biological: TAK-881
Biological: HYQVIA

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drug: Standard therapy for INCS
Drug: LY3650150

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Active, not recruiting
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: Placebo
Locations recently updated

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Enrolling
Hereditary Angioedema
Biological: Normal Saline IV Administration
Biological: NTLA-2002

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatm...

Active, not recruiting
Angioedema
Hives
Drug: Placebo
Drug: Povorcitinib

Trial sponsors

AbbVie logo
Shire logo
Pfizer logo
Sanofi logo
Grifols logo
Lilly logo
A
K
Takeda logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems